Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without and vision loss

Barry Wolf*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations

Abstract

Multiple symptomatic children with biotinidase deficiency have exhibited spastic para- or tetraplegia due to myelopathy with and without vision loss. Although this has been a feature of what has been designated as delayed onset-biotinidase deficiency, myelopathy is likely also on the continuum of clinical features seen in younger children who have had these features attributed to dysfunction of the upper brain rather than of the spinal cord. Because many countries are still not screening their newborns for biotinidase deficiency, the disorder should be included in the differential diagnosis of individuals with myelopathic symptoms. Many of these children have gone weeks to months before they were correctly diagnosed with biotinidase deficiency. Rapid recognition that a child with myelopathy with and without vision loss has biotinidase deficiency will undoubtedly facilitate prompt treatment, increase the possibility of complete recovery and avoid potential residual permanent neurological damage. Newborn screening for biotinidase deficiency would avoid the delay in the diagnosis and treatment of individuals who otherwise may present with myelopathic or other neurological symptoms.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalMolecular Genetics and Metabolism
Volume116
Issue number3
DOIs
StatePublished - Nov 2015

Keywords

  • Biotin-responsive
  • Biotinidase
  • Biotinidase deficiency
  • Myelopathy
  • Scotoma
  • Spastic paraplegia
  • Spastic tetraplegia
  • Spinal disorder
  • Vision loss

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Fingerprint Dive into the research topics of 'Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without and vision loss'. Together they form a unique fingerprint.

Cite this